Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
OPKO Announces Financial and Operating Results
Feb 29, 2016
Consolidated Revenue Increased to $276.2 Million From $25.5 Million for the Three Months Ended December 31, 2015 , and Increased to $491.7 Million from $91.1 Million for the Year Ended December 31, 2015 Clinical Utility Study Demonstrates 4Kscore® Test Reduces Number of Unnecessary Prostate
OPKO's GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco
Feb 24, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) announced today that GeneDx was invited to participate in the Molecular Medicine Tri-Conference 2016, being held at the Moscone North Convention Center in San Francisco, California from March 6 th - 11 th , 2016, and will also be exhibiting
OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
Feb 23, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced dosing of the first patient in a Phase 2a study evaluating the safety of a long-acting Factor VIIa in hemophilia patients. The Phase 2a study is a dose escalation study to determine safety and explore efficacy endpoints in
OPKO to Announce 2015 Fourth Quarter and Full Year Financial Results on February 29, 2016
Feb 23, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three and 12 months ended December 31, 2015 after the close of the U.S. financial markets on Monday, February 29, 2016 .
OPKO Health to Present at the RBC Capital Markets Global Healthcare Conference
Feb 18, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, February 23, 2016 at 3:05 PM (EST) . The presentation will be webcast on the OPKO Investor Relations page of the
Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer
Feb 09, 2016
4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) announced today the results of a study for the 4Kscore® Test's clinical utility in
OPKO's GeneDx to Present at Personalized Medicine World Conference
Jan 22, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that Marc D. Grodman , MD, Chief Executive Officer of its BioReference/GeneDx subsidiaries, will speak at this year's  Personalized Medicine World Conference , Silicon Valley . Dr.
OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference
Jan 06, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the J.P. Morgan 34 th Annual Healthcare Conference on Tuesday, January 12, 2016 at 4:00 PM (PT) . The presentation will be webcast on the OPKO Investor Relations page of the corporate
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Jan 05, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") continue to be convertible by holders of such Notes through March 31, 2016 . The Company has elected to satisfy its conversion obligation under the Notes
OPKO's GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer Panel Reveals New Risks
Dec 21, 2015
Largest Published Study to Date Supports Testing Changes and Development of New Treatment Options MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) through its subsidiary GeneDx, today announced results from the largest published study to date of patients who received hereditary genetic
OPKO's GeneDx Subsidiary and North Shore-LIJ Health System Form Strategic Alliance for Genetic Testing
Dec 14, 2015
Collaboration will drive the use of medically necessary genomic testing to improve patient care
OPKO's GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders
Dec 09, 2015
Study reveals new disease causing genes MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today through its subsidiary GeneDx, results from a retrospective review of molecular diagnostic testing by Whole Exome Sequencing (WES). The peer-reviewed study, " Clinical Application of Whole
OPKO Health to Present at the Oppenheimer 26th Annual Healthcare Conference
Dec 02, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 26 th Annual Healthcare Conference on Tuesday, December 8 th , 2015 at 8:00 AM (ET) in New York . OPKO's senior management will provide a review of recent corporate
OPKO Health to Present at the Jefferies Autumn 2015 Global Healthcare Conference
Nov 17, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Autumn 2015 Healthcare Conference on Wednesday, November 18, 2015 , at 2:00 GMT in London, England . The presentation will be webcast on the OPKO Investor Relations page of
OPKO Licensee TESARO Announces the Launch of VARUBI(TM) (Rolapitant) in the United States
Nov 16, 2015
VARUBI™(rolapitant) provides extended protection for chemotherapy-induced nausea and vomiting (CINV) in the delayed phase (25-120 hours) with a single dose as part of an antiemetic regimen More than half of patients undergoing emetogenic chemotherapy may experience delayed CINV, even when
OPKO 4Kscore Test Receives Category I CPT Code Approval
Nov 12, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code for its 4Kscore® Test, the only blood test that accurately identifies an individual patient's
OPKO Announces Third Quarter Financial and Operating Results
Nov 09, 2015
Consolidated Revenue Increased to $143.0 Million From $19.8 million for the Three Months Ended September 30, 2015 , and Increased to $215.5 Million from $65.6 Million for the Nine Months Ended September 30, 2015 Closed Acquisition of Bio-Reference Laboratories on August 20, 2015 Announced Genomics
OPKO Health Refinances Bio-Reference Laboratories Credit Facility
Nov 06, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced today that it has successfully closed on a new five-year $175.0 million secured revolving credit facility with JPMorgan Chase . The new facility replaced Bio-Reference Laboratories' previous $120.0 million secured revolving
OPKO to Announce Third Quarter Operating and Financial Results on November 9, 2015
Nov 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK), a multinational biopharmaceutical and diagnostics company, will release operating and financial results for the three months ended September 30, 2015 , after the close of the U.S. financial markets on Monday, November 9, 2015 .
Additional Phase 3 Data Supporting OPKO's Rayaldee as a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at Kidney Week 2015
Nov 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) , a multinational biopharmaceutical and diagnostics company, announces that additional Phase 3 data on Rayaldee™ as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at Kidney Week
Displaying 101 - 120 of 363